The comparison of numbers and suppressive function of Treg in a population of severe psoriatic patients in peripheral blood by flowcytometry and the assessment of a Th17 (e.g. IL-17) cytokine profile from the supernatants. Furthermore, the relation…
ID
Source
Brief title
Condition
- Autoimmune disorders
- Epidermal and dermal conditions
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Numbers of Treg of severe psoriasis patients as compared to the results found
in CMO study 2004/265.
Suppressive capacity of peripheral Treg of severe psoriatic patients as
compared to CMO study 2004/265.
Describe the cytokine profile of Treg.
Secondary outcome
Show the presence of Treg and Th17 cells in the skin by means of
immunofluorescent inveastigation of skin biopsies, with emphasis on the
Treg-Th17 interaction.
Background summary
Naturally occurring CD4+CD25+ regulatory T cells (Treg) are a distinct subtype
of T cells with a suppressive function, by which these cell control effector
T-cell activity. In psoriasis, the suppressive function of Treg is disturbed,
leading to unrestrained T-cell proliferation and activity by which thechronic
skin disease psoriasis is initiated and maintained. Furthermore, there is
evidence for a prominent role of Th17 cells in the pathogenesis of psoriasis.
The link between Treg and Th17 T cells has not yet been studied and is unclear.
Study objective
The comparison of numbers and suppressive function of Treg in a population of
severe psoriatic patients in peripheral blood by flowcytometry and the
assessment of a Th17 (e.g. IL-17) cytokine profile from the supernatants.
Furthermore, the relation between Treg and Th17 cells will be studied in target
tissue, in this case the skin, by means of immunofluorescence investigation.
Study design
Cross-sectional pilot-study
Study burden and risks
One visit in which peripheral blood and one 4 mm skin biopsy will be withdrawn.
(30 mins)
René Descartesdreef 1
6525 GL Nijmegen
Nederland
René Descartesdreef 1
6525 GL Nijmegen
Nederland
Listed location countries
Age
Inclusion criteria
Age >18
No successful systemic antipsoriatic treatment
Severe plaque-type psoriasis (Psoriasis Area and Severity Index (PASI) >10)
Exclusion criteria
Other forms of psoriasis other than plaque-type psoriasis
Mild psoriasis
Age < 18
Concurrent systemic antipsoriatic treatment
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL26461.091.08 |